Smad3 deficiency protects mice against high-fat diet-induced obesity and insulin resistance, suggesting it as a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Does not support clinical use; leaves open Smad3 as therapeutic target in human metabolic disease.
Smad3 is a multifaceted regulator in adipose physiology and the pathogenesis of obesity and type 2 diabetes, suggesting that Smad3 may be a potential target for the treatment of obesity and its associated disorders.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: